Cargando…
Targeting the CD47-SIRPα Axis: Present Therapies and the Future for Cutaneous T-cell Lymphoma
The loss of CD47 on aging cells serves as a signal to macrophages to eliminate the target. Therefore, CD47 is a “do-not-eat-me” sign preventing macrophagal phagocytosis via interaction with its ligand SIRPα. Malignant lymphocytes of mycosis fungoides and Sézary syndrome express CD47 highly, thus, be...
Autores principales: | Xiao, Amy, Akilov, Oleg E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9688096/ https://www.ncbi.nlm.nih.gov/pubmed/36429020 http://dx.doi.org/10.3390/cells11223591 |
Ejemplares similares
-
Targeting CD47-SIRPα axis for Hodgkin and non-Hodgkin lymphoma immunotherapy
por: Zhao, Pengcheng, et al.
Publicado: (2023) -
Insights into CD47/SIRPα axis-targeting tumor immunotherapy
por: Zhang, Xuyao, et al.
Publicado: (2018) -
Advances in Anti-Tumor Treatments Targeting the CD47/SIRPα Axis
por: Zhang, Wenting, et al.
Publicado: (2020) -
Cancer Therapy Targeting CD47/SIRPα
por: Dizman, Nazli, et al.
Publicado: (2021) -
Targeting the CD47-SIRPα signaling axis: current studies on B-cell lymphoma immunotherapy
por: Zhang, Jin, et al.
Publicado: (2018)